阿帕替尼用于小细胞肺癌多线治疗后的挽救治疗  

Apatinib as Salvage Therapy for Heavily Pretreated SCLC

作　　者：李芳芳[1] 陶海涛[2] Fangfang LI;Haitao TAO(Department of State Guest,Institute of Health Management,the Chinese PLA General Hospital,Beijing 100853,China;Department of Oncology,the Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]中国人民解放军总医院健康管理研究院国宾部,北京100853 [2]中国人民解放军总医院健康管理研究院肿瘤内科,北京100853

出　　处：《中国肺癌杂志》2018年第7期565-570,共6页Chinese Journal of Lung Cancer

摘　　要：小细胞肺癌(small cell lung cancer,SCLC)恶性程度高,在放、化疗失败后缺乏有效治疗手段,抗血管生成治疗在晚期SCLC中表现出一定的疗效。阿帕替尼是一种口服小分子酪氨酸激酶抑制剂,通过抑制血管内皮生长因子受体2(vascular endothelial growth factor receptor 2,VEGFR-2)达到抗血管生成的作用,在SCLC上的应用报道较少。本文报道了1例合并有Gilbert综合征的SCLC患者,在4线化疗失败后接受了阿帕替尼的挽救治疗,1个月后达到部分缓解(partial remission,PR),最终获得了5个月的无进展生存时间。由于胆红素代谢障碍,该患者在阿帕替尼治疗过程中反复出现3级的高胆红素血症,余不良反应耐受良好。阿帕替尼在晚期SCLC挽救治疗中的作用值得进一步探索。Small cell lung cancer （SCLC） was highly malignant and lack effective treatment after the failure of radiotherapy and chemotherapy. Antiangiogenic therapy had shown a certain effect in advanced SCLC. Apatinib, a new potent oral smaU-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 （VEGFR-2）, showed the effect of anti-angiogenesis. However, the efficacy in SCLC was rarely reported. We reported 1 case of advanced SCLC with Gilbert syndrome, the patient received Apatinib after the failure of 4 lines of chemotherapy3 and achieved a partial response according to the Response Evaluation Criteria in Solid Tumors （RECIST） 1.1 standard after one month. The progression-free survival （PFS） was 5 months. Apatinib was well tolerated except recurrent grade 3 hyperbilirubinemia because of the metabolic disorder of Bilirubin. Salvage treatment with Apatinib for advanced SCLC deserved further exploration.

关 键 词：小细胞肺癌 抗血管生成 阿帕替尼 GILBERT综合征 

分 类 号：R734.2[医药卫生—肿瘤]